ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 3ÔÂ20ÈÕ£¬£¬£¬Ê¯Ò©¼¯ÍÅ£¨1093.HK£©Í¨¸æ£¬£¬£¬¼¯ÍÅ¿ª·¢µÄ¿¹ÌåÒ©ÎïżÁªÎAntibody-Drug Conjugate£©SYS6023ÒÑ»ñµÃÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú×¼¡£¡£¡£¡£¡£SYS6023ÊÇÒ»¿îµ¥¿Ë¡¿¹ÌåÒ©ÎïżÁªÎ£¬£¬»ñÅúÁÙ´²µÄ˳Ӧ֢ΪÍíÆÚʵÌåÁö¡£¡£¡£¡£¡£
2. 3ÔÂ21ÈÕ£¬£¬£¬¿µÆÓÉúÎïÒ½Ò©Ðû²¼Æä×ÔÖ÷Ñз¢µÄС·Ö×Ó1ÀàÐÂÒ©KPG-818½ºÄÒÔÚÖйú»ñÅúÁÙ´²£¬£¬£¬Ä⿪·¢ÖÎÁÆÏµÍ³ÐÔºì°ßÀÇ´¯£¨SLE£©¡£¡£¡£¡£¡£KPG-818ÊÇ¿µÆÓÉúÎïÒ½Ò©Éè¼Æ¿ª·¢µÄÐÂÒ»´ú¿Ú·þ·Ö×Ó½ºÃâÒßµ÷ÀíÒ©Îï¡£¡£¡£¡£¡£
3. 3ÔÂ19ÈÕ£¬£¬£¬ÎäÌïÐû²¼FDAÒѾ¼ÓËÙÅú×¼ponatinib£¨ÉÌÆ·Ãû£ºIclusig£©µÄÔö²¹ÐÂÒ©ÉêÇ루sNDA£©£¬£¬£¬¼´ÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆÐÂÕï¶Ï·Ñ³ÇȾɫÌåÑôÐÔ¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¡£¡£¡£¡£¨Ph+ ALL£©³ÉÄ껼Õß¡£¡£¡£¡£¡£
4. 3ÔÂ19ÈÕ£¬£¬£¬±±¾©Î°µÂ½ÜÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾×ÔÖ÷¿ª·¢µÄIÀàÐÂÒ©×¢ÉäÓÃVDJ010ÁÙ´²ÊÔÑéÉêÇ룬£¬£¬»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©µÄÅú×¼£¬£¬£¬Ë³Ó¦Ö¢ÎªÀ£ÑñÐԽ᳦Ñ×£¨UlcerativeColitis£¬£¬£¬UC£©¡£¡£¡£¡£¡£
1. 3ÔÂ20ÈÕ£¬£¬£¬Capstan TherapeuticsÐû²¼ÀÖ³ÉÍê³ÉÁË1.75ÒÚÃÀÔªµÄÓâ¶îÈϹºBÂÖÈÚ×Ê£¬£¬£¬Ëù»ñµÃµÄ×ʽð½«ÓÃÓÚÍÆ½øCapstanµÄÖ÷´òÌåÄÚǶºÏ¿¹ÔÊÜÌåTϸ°û£¨CAR-T£©ºòÑ¡ÁÆ·¨CPTX2309ÔÚ×ÔÉíÃâÒß¼²²¡ÖеÄÔçÆÚÁÙ´²¿´·¨ÑéÖ¤£¬£¬£¬²¢½øÒ»²½¿ª·¢CapstanµÄ°ÐÏòÖ¬ÖÊÄÉÃ׿ÅÁ££¨tLNP£©¹ÜÏß¡£¡£¡£¡£¡£
1. 3ÔÂ20ÈÕ£¬£¬£¬ÏÃÃÅ´óѧҽѧԺÄÔ¿ÆÑ§ÖÐÐÄÕÔÓ±¿¡ÍŶÓÔÚ Neuron £¨Éñ¾¿ÆÑ§¶¥¼¶ÆÚ¿¯£©½ÒÏþÁËÌâΪ P-tau217 correlates with neurodegeneration in Alzheimer¡¯s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy µÄÎÄÕ¡£¡£¡£¡£¡£±¾Ñо¿Ð§¹ûÅú×¢Õë¶Ô p-tau217 µÄÃâÒßÖÎÁÆÊÇÒ»ÖÖÓÐÓõIJßÂÔ£¬£¬£¬¿ÉÒÔ¸ÉÔ¤ tau ÂѰ׼²²¡Ð¡ÊóÄ£×Ó£¨PS19£©ÖеÄÏà¹Ø²¡ÀíºÍÉñ¾ÍËÐÐÐÔ²¡±ä£¬£¬£¬²¢ÇÒ¸±×÷ÓúÜС£¬£¬£¬ÊÇ AD Ïà¹ØÉñ¾ÐÔÍËÐм²²¡µÄDZÔÚÖÎÁưе㡣¡£¡£¡£¡£
[1]Zhang et al. P-tau217 correlates with neurodegeneration in Alzheimer¡¯s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy, Neuron (2024).
Ïà¹ØÐÂÎÅ